Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602515 | 0.90 | PDE4A (0.60) | PDE4AKCNH2KDM4EMETF10 | |
| SCHEMBL7167976 | 0.89 | PDE4A (0.59) | PDE4AKCNH2MAOB | |
| SCHEMBL7172242 | 0.89 | PDE4A (0.59) | PDE4AKCNH2METKITFLT3 | |
| SCHEMBL7172238 | 0.89 | PDE4A (0.56) | PDE4AKCNH2KDM4ENPC1RAB9A | |
| SCHEMBL7169646 | 0.88 | PDE4A (0.62) | PDE4AKCNH2NPC1RAB9A | |
| SCHEMBL7175717 | 0.87 | PDE4A (0.62) | PDE4AKCNH2KDM4EMAOBMET | |
| SCHEMBL7169134 | 0.87 | PDE4A (0.60) | PDE4AKCNH2MAOBMETKIT | |
| SCHEMBL7684539 | 0.87 | PDE4A (0.59) | PDE4AKCNH2KDM4ERAB9AL3MBTL1 | |
| SCHEMBL7171697 | 0.87 | PDE4A (0.56) | PDE4AKCNH2L3MBTL1MET | |
| SCHEMBL7172279 | 0.86 | PDE4A (0.60) | PDE4AKCNH2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541480-B2 | Controlling cytokines | SUNTORY LIMITED (JP) | 2003-04-01 | — | — | US | disclosed |
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6297248-B1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | SUNTORY LIMITED (JP) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006935-A1 | 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor | PDE3A, PDE5A, PDE3B | PDE4A 4/4885KCNH2 559/4885KDM4E 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.